Alnylam Pharmaceuticals Inc (ALNY) reports strong financial performance with significant growth in TTR franchise and ...

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained ...

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a ...

Christine Lindenboom; Chief Corporate Communications Officer; Alnylam Pharmaceuticals. Yvonne Greenstreet; Chief Executive Officer, Director; Alnylam Pharmaceuticals ...

--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY) (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based company said ...

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...

Alnylam Pharmaceuticals said its RNAi therapeutic vutrisiran received a positive opinion recommending approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Discover Alnylam Pharmaceuticals' robust Q1 2025 earnings, highlighted by a 28% revenue growth and the successful launch of AMVUTTRA for ...

Alnylam Pharmaceuticals, a $32.4 billion biotech company with a "GOOD" InvestingPro Financial Health rating, reported its Q1 2025 earnings, surpassing expectations with an EPS of -0.01 against a ...